CARM - Wutah pendapatan YoY sajrone 12 wulan kepungkur Carisma Therapeutics

Leadership in macrophage therapy against tumors and the alliance with Moderna are driving the development of Carisma Therapeutics (CARM). The historical year-over-year revenue growth trend for the last 12 months within the GURU.Markets system captures current dynamics, where the -82.20 level records the latest values. Professional management is optimizing expenses, while high utilization of sterile laboratories ensures the uninterrupted production of innovative cell products.
Ringkesan rincian data analitis carismatx.com (CARM)

This metric is calculated as the percentage change in revenue over a rolling 12-month period relative to the same window from the previous year. The metric measures business expansion dynamics and the speed of market niche capture. For Carisma Therapeutics (CARM), the value -82.20 reflects the monetization rates of unique developments in CAR-M therapy. The company's patent leadership should convert into a steady cash inflow. By analyzing this 12-month YoY sales growth chart, an investor assesses the actual scalability of the biotech startup.